Reduced hours mean fewer serious medical errors by interns

Food Insecurity and the Dangers of Infant Formula Dilution

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from June 2025.

January 30th 2023

MNV-201 receives fast track, rare pediatric disease to treat Pearson Syndrome

June 30th 2025

Demystifying Infant Formula

MNV-201 is being evaluated in phase 2 clinical trials for treatment of the ultra-rare, life-threatening mitochondrial disorder affecting children.

October 11th 2022

Weekly review: ACIP meets and votes, marstacimab data for hemophilia, and more

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Mercedes E. Gonzalez, MD

FDA news in pediatrics: June 2025

Roflumilast cream 0.05% is being studied for mild-to-moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.

Related Content

Morgan Ebert, Managing Editor

July 1st 2025

Food Insecurity and the Dangers of Infant Formula Dilution

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from June 2025.

January 30th 2023

MNV-201 receives fast track, rare pediatric disease to treat Pearson Syndrome

June 30th 2025

Demystifying Infant Formula

MNV-201 is being evaluated in phase 2 clinical trials for treatment of the ultra-rare, life-threatening mitochondrial disorder affecting children.

October 11th 2022

Weekly review: ACIP meets and votes, marstacimab data for hemophilia, and more

Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Mercedes E. Gonzalez, MD